Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence.
anti-cancer
combination regimen
navitoclax (ABT-263)
non-solid tumor
solid tumor
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
28 Aug 2021
28 Aug 2021
Historique:
received:
31
07
2021
revised:
25
08
2021
accepted:
25
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Combination therapy emerges as a fundamental scheme in cancer. Many targeted therapeutic agents are developed to be used with chemotherapy or radiation therapy to enhance drug efficacy and reduce toxicity effects. ABT-263, known as navitoclax, mimics the BH3-only proteins of the BCL-2 family and has a high affinity towards pro-survival BCL-2 family proteins (i.e., BCL-XL, BCL-2, BCL-W) to induce cell apoptosis effectively. A single navitoclax action potently ameliorates several tumor progressions, including blood and bone marrow cancer, as well as small cell lung carcinoma. Not only that, but navitoclax alone also therapeutically affects fibrotic disease. Nevertheless, outcomes from the clinical trial of a single navitoclax agent in patients with advanced and relapsed small cell lung cancer demonstrated a limited anti-cancer activity. This brings accumulating evidence of navitoclax to be used concomitantly with other chemotherapeutic agents in several solid and non-solid tumors that are therapeutically benefiting from navitoclax treatment in preclinical studies. Initially, we justify the anti-cancer role of navitoclax in combination therapy. Then, we evaluate the current evidence of navitoclax in combination with the chemotherapeutic agents comprehensively to indicate the primary regulator of this combination strategy in order to produce a therapeutic effect.
Identifiants
pubmed: 34575429
pii: pharmaceutics13091353
doi: 10.3390/pharmaceutics13091353
pmc: PMC8468743
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Ministry of Higher Education, Malaysia
ID : FRGS/1/2019/SKK06/UKM/02/7
Références
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Carcinogenesis. 2011 Aug;32(8):1143-50
pubmed: 21515914
J Clin Oncol. 2012 May 10;30(14):1670-7
pubmed: 22454413
Lancet Oncol. 2016 Sep;17(9):1272-82
pubmed: 27460442
Endocr Connect. 2019 Jun;8(6):754-763
pubmed: 31071680
Curr Opin Genet Dev. 2011 Feb;21(1):12-20
pubmed: 21236661
Open Biol. 2018 May;8(5):
pubmed: 29769323
Cell Death Dis. 2018 Sep 24;9(10):986
pubmed: 30250075
Cancer Biol Ther. 2016;17(1):27-35
pubmed: 26575826
J Clin Endocrinol Metab. 2015 Jan;100(1):E77-81
pubmed: 25353071
Cancer Res. 2011 Jul 1;71(13):4518-26
pubmed: 21546570
Blood. 2013 Aug 29;122(9):1587-98
pubmed: 23881917
Genes Chromosomes Cancer. 2013 Nov;52(11):1053-64
pubmed: 23999921
J Nutr Biochem. 2016 May;31:28-37
pubmed: 27133421
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Clin Adv Hematol Oncol. 2014 Apr;12(4):224-9
pubmed: 25003352
Nat Rev Mol Cell Biol. 2014 Jan;15(1):49-63
pubmed: 24355989
Nat Rev Clin Oncol. 2011 Jun 21;8(10):611-9
pubmed: 21691321
Biochim Biophys Acta. 2013 Dec;1833(12):2980-2987
pubmed: 23954445
Mol Cell. 2010 Dec 10;40(5):823-33
pubmed: 21145489
Clin Cancer Res. 2012 Jun 1;18(11):3163-9
pubmed: 22496272
Leukemia. 2007 Aug;21(8):1773-82
pubmed: 17525724
Mol Cancer Ther. 2014 Mar;13(3):565-75
pubmed: 24019208
Sci Rep. 2019 Feb 6;9(1):1514
pubmed: 30728391
J Craniofac Surg. 2016 Jul;27(5):1361-6
pubmed: 27391504
Horm Cancer. 2018 Oct;9(5):295-325
pubmed: 29987748
Nat Rev Cancer. 2014 Aug;14(8):547-58
pubmed: 25030953
Nat Genet. 2016 Aug;48(8):848-55
pubmed: 27348297
Cell Death Differ. 2015 Jul;22(7):1071-80
pubmed: 25952548
Cell. 2011 Oct 14;147(2):275-92
pubmed: 22000009
Biomater Sci. 2020 Apr 15;8(8):2264-2273
pubmed: 32134074
Oncologist. 1999;4(1):17-33
pubmed: 10337368
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Cancer Res. 2020 Feb 15;80(4):832-842
pubmed: 31888889
Cancer Res. 2016 Mar 15;76(6):1303-4
pubmed: 26979790
Cell Death Dis. 2020 Jun 8;11(6):443
pubmed: 32513939
J Clin Oncol. 2011 Mar 1;29(7):909-16
pubmed: 21282543
Nat Commun. 2016 Jan 29;7:10582
pubmed: 26822383
Front Pharmacol. 2020 Nov 26;11:564108
pubmed: 33381025
Cancer Res. 2008 May 1;68(9):3421-8
pubmed: 18451170
Int J Oncol. 2019 Feb;54(2):407-419
pubmed: 30570109
Cell Death Dis. 2015 Mar 05;6:e1675
pubmed: 25741600
Am J Cancer Res. 2017 May 01;7(5):1016-1036
pubmed: 28560055
Leukemia. 2019 Jun;33(6):1360-1372
pubmed: 30568173
Commun Integr Biol. 2012 Nov 1;5(6):557-65
pubmed: 23336025
Haematologica. 2014 Sep;99(9):1465-71
pubmed: 24951466
Curr Med Chem. 2017;24(40):4488-4514
pubmed: 28901269
Drug Des Devel Ther. 2014 Aug 14;8:1083-7
pubmed: 25152614
Eur J Pharmacol. 2019 Nov 5;862:172655
pubmed: 31494078
Clin Cancer Res. 2008 Jun 1;14(11):3268-77
pubmed: 18519752
Cancer Res. 1967 Jul;27(7):1258-63
pubmed: 4952914
Front Pharmacol. 2018 Nov 13;9:1300
pubmed: 30483135
Oncologist. 2006 Apr;11(4):325-35
pubmed: 16614228
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
J Med Chem. 2014 Oct 9;57(19):7874-87
pubmed: 24946140
Expert Rev Anticancer Ther. 2016 May;16(5):515-21
pubmed: 26999568
Cell Oncol (Dordr). 2019 Jun;42(3):357-368
pubmed: 30919222
Mol Pharmacol. 2019 Oct;96(4):419-429
pubmed: 31467029
Cell Death Differ. 2018 Jan;25(1):3-6
pubmed: 29227986
Ann Intern Med. 1970 Dec;73(6):881-95
pubmed: 5525541
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Neoplasia. 2006 Mar;8(3):163-72
pubmed: 16611409
Cells. 2020 May 21;9(5):
pubmed: 32455818
J Clin Oncol. 2012 Feb 10;30(5):488-96
pubmed: 22184378
Clin Cancer Res. 2017 Dec 15;23(24):7558-7568
pubmed: 28974549
Cancer Chemother Pharmacol. 2010 Oct;66(5):869-80
pubmed: 20099064
J Clin Oncol. 2013 Apr 20;31(12):1592-605
pubmed: 23509311
Mol Cancer Ther. 2010 Mar;9(3):545-57
pubmed: 20179162
Blood. 2011 Sep 29;118(13):3645-56
pubmed: 21813447
Toxicol In Vitro. 2018 Feb;46:229-236
pubmed: 28947240
Oncol Rep. 2009 Nov;22(5):1237-45
pubmed: 19787245
Pediatr Blood Cancer. 2008 May;50(5):1018-25
pubmed: 17849473
Cancer Cell. 2003 Jan;3(1):17-22
pubmed: 12559172
Blood. 2014 Oct 9;124(15):2400-7
pubmed: 25145343
Cancer Res. 2000 Nov 1;60(21):6101-10
pubmed: 11085534
Curr Drug Discov Technol. 2015;12(1):3-20
pubmed: 26033233
Lancet Oncol. 2014 Mar;15(3):323-32
pubmed: 24508103
Cancer Res. 2012 Jun 15;72(12):3069-79
pubmed: 22525702
Sci Adv. 2016 May 27;2(5):e1600200
pubmed: 27386546
Thyroid. 2013 Oct;23(10):1277-83
pubmed: 23489023
Thyroid. 2019 Apr;29(4):540-548
pubmed: 30869573